VRDN – viridian therapeutics, inc. (US:NASDAQ)

News

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Viridian Therapeutics (NASDAQ:VRDN) was given a new $41.00 price target on by analysts at Truist Financial Corporation.
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com